Start here if you're new
what it is
MBX Biosciences makes lab-made drugs for hormone and metabolism disorders.
how it gets paid
MBX is pre-commercial: essentially no product revenue. Pipeline rows below show program focus, not % of sales.
what just happened
MBX posted about -$0.49 EPS in its last reported quarter (Q4 2025) and still had no product revenue.
At a glance
n/a balance sheet
-$5.82 fy2024 eps (loss, cited)
~$1B market cap
small cap
NASDAQ
What they do
MBX Biosciences makes lab-made drugs for hormone and metabolism disorders.
MBX has 43 employees and three named programs. That is a tiny team chasing big disease markets. If you own it, your bet is on the PEP platform, which is a lab engine for peptide drugs. The upside is focus. The downside is one bad trial can leave you with no backup business.
How they make money
n/a
annual revenue
canvuparatide (MBX 2109)
$0M
MBX 1416
$0M
obesity portfolio
$0M
discovery and pre-clinical candidates
$0M
$0 and 0% bars: no product revenue to chart—rows are pipeline attention, not sales mix.
The products that matter
lead peptide candidate
Canvuparatide
lead asset · thesis driver
This is the asset the whole page keeps orbiting. With $0 revenue today, one lead program can carry most of the valuation — or break it.
core thesis
pre-revenue drug pipeline
Clinical Pipeline
$0 revenue today
The pipeline is the only path from research spend to product sales. Right now it contributes promise, not revenue.
future value
balance sheet buffer
Cash Position
~$459M cash (pro forma YE 2025)
This is not a product, but it matters as much as one. In pre-revenue biotech, cash is what keeps the timeline alive.
time
Key numbers
$38.09
share price
This is your starting line. Everything else is upside or downside from here.
~$1B
market cap
The market already gives MBX about $1B of value, before a commercial sale exists.
-$5.82
FY2024 EPS (loss)
Large FY loss in 2024; 2025 loss per share was smaller (~-$2.38 here)—verify diluted vs basic in your source.
$0M
debt
No long-term debt gives you less balance sheet stress. It does not give you revenue.
Financial health
n/a
strength
- balance sheet grade n/a
- long-term debt $0M (0% of capital)
n/a — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for MBX right now.
source: institutional data · return history unavailable
What just happened
verify Q vs FY est.
MBX posted about -$0.49 EPS in Q4 2025 and still had no product revenue.
Full-year 2025 diluted loss was about $2.38 per share versus about $5.82 in 2024. You are looking at a company that spends before it sells.
$0M
revenue
-$0.49
quarter eps
-$2.38
fy2025 eps
the number that mattered
The quarter's ~-$0.49 EPS matters because it shows the business is still losing money before any product sales show up.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is canvuparatide clinical disappointment. MBX has $0 revenue, so a weak dataset would not dent one segment — it would force investors to rethink the whole story.
med
canvuparatide does not de-risk the story
This is the lead asset. If the data disappoints, the market stops valuing future commercial potential and starts valuing cash, time, and what is left in the pipeline.
With $0 revenue today, one failed readout can reset the entire ~$1B equity narrative.
med
cash becomes the thesis instead of the bridge
~$459M pro forma cash (YE 2025) is meaningful, but pre-revenue biotech eventually needs one of three things: better data, a partner, or more capital. If timelines slip, financing risk moves from background noise to headline.
That would pressure the stock even without bad science because dilution fear alone can reprice small-cap biotech.
med
the company is still too binary
There is no operating diversification to hide behind. No revenue stream offsets clinical uncertainty, and no mature product base cushions investors while they wait.
The result is simple: you are exposed to timeline slippage and sentiment swings at the same time.
With $0 revenue, the combined risk picture is unusually clean: the stock works if clinical progress keeps buying time for the cash runway to matter less, and it struggles if cash starts mattering more than science.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
cash on hand
Pro forma cash of roughly $450M+ (YE 2025) is the number that gives management time. If that buffer falls without a de-risking catalyst, your margin for error shrinks fast.
risk
canvuparatide data quality
This is the break-or-prove variable. Watch the lead program before you watch day-to-day stock moves.
calendar
next company update
Use the next update to judge progress against cash burn. In pre-revenue biotech, silence is rarely neutral.
trend
how close the stock stays to its high
At $38.09 versus a $45 high, the market is leaning optimistic. If confidence cracks, small-cap biotech can retrace much faster than it climbed.
Analyst rankings
short-term outlook
speculative upside
The average target is $54.20 versus a $38.09 stock price. In human-speak: analysts still like the payoff if the science cooperates.
risk profile
high
A $5–$45 52-week range is what binary catalyst risk looks like when it gets a chart.
chart momentum
event-driven
This name trades on trial expectations and financing confidence more than smooth technical trends.
earnings predictability
40 / 100
The income statement will stay noisy because there is no commercial revenue stream making the numbers behave.
source: institutional data
Institutional activity
institutional ownership data for MBX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$38
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive